Form 4: Gossamer Bio Director John D. Quisel Granted 115,000 Stock Options

Gossamer Bio, Inc. Director John D. Quisel was granted 115,000 stock options with an exercise price of $1.36 per share, as part of the company's Non-Employee Director Compensation Program.

Summary

• John D. Quisel, a Director of Gossamer Bio, Inc. (GOSS), was granted 115,000 stock options.
• The options have an exercise price of $1.36 per share.
• The grant date for these options was June 25, 2025.
• The options expire on June 24, 2035.
• The award was made under the company's Non-Employee Director Compensation Program.
• The options will fully vest and become exercisable on the first anniversary of the grant date (June 25, 2026) or the next annual meeting of stockholders, whichever occurs first, contingent on Mr. Quisel's continued service on the board.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns management/director incentives with shareholder interests. It's a routine compensation event, not indicative of extraordinary positive or negative news, hence a moderately positive score.

Positives

• The grant of stock options to Director John D. Quisel aligns his interests with those of shareholders, incentivizing long-term company performance.
• The award is part of a pre-existing Non-Employee Director Compensation Program, indicating a structured approach to executive and director remuneration.

Negatives

• No direct negatives are presented in this Form 4 filing, as it primarily reports a compensation event.

Risks

• The value of the stock options is dependent on the future stock price of Gossamer Bio, Inc., meaning the options could become worthless if the stock price does not exceed the exercise price of $1.36.
• Vesting of the options is subject to the reporting person's continued service on the board of directors, posing a risk if service is terminated prior to vesting.

Future Outlook

The stock options granted to Director John D. Quisel are set to fully vest and become exercisable on the first anniversary of the grant date (June 25, 2026) or the next annual meeting of the Issuer's stockholders, whichever occurs first, provided Mr. Quisel continues his service on the board.

Management Comments

• Award made pursuant to Non-Employee Director Compensation Program.
• The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Industry Context

This filing is a routine disclosure of director compensation in the biotechnology and pharmaceutical industry. Companies in this sector often use equity-based compensation, such as stock options, to attract and retain qualified directors and align their interests with long-term shareholder value creation, particularly given the long development cycles and high-risk nature of drug discovery.

Comparison to Industry Standards

• This Form 4 reports a standard equity grant to a non-employee director, which is a common practice across publicly traded companies, including those in the biotechnology sector.
• While the specific number of options (115,000) and exercise price ($1.36) are specific to Gossamer Bio, the mechanism of granting stock options as part of a non-employee director compensation program is consistent with global benchmarks for corporate governance and executive compensation.
• Direct comparisons to specific companies or projects are not applicable as this is a compensation disclosure, not a performance report.

Corporate Governance

Related Party Transactions

• The grant of 115,000 stock options to John D. Quisel, a Director of Gossamer Bio, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders by incentivizing an increase in the company's stock price. However, it also represents potential future dilution if the options are exercised.
• Employees: No direct impact on general employees is mentioned, but it reinforces the company's use of equity-based compensation.

Next Steps

• The stock options will vest on the first anniversary of the grant date (June 25, 2026) or the next annual meeting of stockholders, whichever is earlier, subject to continued board service.
• John D. Quisel may choose to exercise these options at any point after vesting and before the expiration date of June 24, 2035, provided the stock price is above the exercise price.

Key Dates

Keywords

Gossamer Bio, GOSS, SEC Form 4, Stock Options, Director Compensation, Equity Grant, Insider Transaction, John D. Quisel, Biotechnology, Pharmaceuticals